<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45-pharmaceutics-10-00039">
 <label>45.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Walker</surname>
    <given-names>D.K.</given-names>
   </name>
   <name>
    <surname>Abel</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Comby</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Muirhead</surname>
    <given-names>G.J.</given-names>
   </name>
   <name>
    <surname>Nedderman</surname>
    <given-names>A.N.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>D.A.</given-names>
   </name>
  </person-group>
  <article-title>Species differences in the disposition of the CCR5 antagonist, UK-427, 857, a new potential treatment for HIV</article-title>
  <source>Drug Metab. Dispos.</source>
  <year>2005</year>
  <volume>33</volume>
  <fpage>587</fpage>
  <lpage>595</lpage>
  <pub-id pub-id-type="doi">10.1124/dmd.104.002626</pub-id>
  <?supplied-pmid 15650075?>
  <pub-id pub-id-type="pmid">15650075</pub-id>
 </element-citation>
</ref>
